Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Inclusion criteria: * LMT ineligible * Participants must meet the lipid criteria of "low to moderate CHD risk" as defined by National Cholesterol Education Program Adult Treatment Panel III Framingham Point Scores (NCEP ATP III) * HDL-C \<40 mg/dL (1.03 mmol/L) in males and \<50 mg/dL (1.29 mmol/L) in females * Triglyceride (TG) level \<300 mg/dL (3.39 mmol/L). * Fasting serum glucose (FSG) at Visit 1 AND Visit 2 \<126 mg/dL (\<7 mmol/L) * Hemoglobin A1c (HbA1c) level \<6.5% * Participant willing to use acceptable method of contraception during the study, including the 14-day follow-up period Exclusion criteria: * History of malignancy ≤5 years prior to signing informed consent, except for adequately-treated basal cell or squamous cell skin cancer or in situ cervical cancer * Participation in a study with an investigational compound (non-lipid-modifying) within 30 days * Pregnant, breastfeeding, or expecting to conceive, or father a child during the study, including the 14-day follow-up period * Consumption of more than 3 alcoholic drinks on any given day or more than 14 drinks per week * Engages in or plans to engage in vigorous exercise or an aggressive diet regimen during the study * Diabetes mellitus, based on medical history, FSG ≥126 mg/dL (7 mmol/L), and HbA1c ≥6.5% * Risk factors for coronary heart disease * Active or chronic hepatobiliary or hepatic disease * Active peptic ulcer disease within 3 months of Visit 1 * History of hypersensitivity or allergic reaction to niacin or niacin-containing products * Episode of gout within 1 year of Visit 1, unless currently stable on allopurinol * Taking an LMT (including statins, bile acid sequestrants, fibrates and niacin \>50 mg as monotherapy or coadministered with other LMTs) * Use of over-the- counter or traditional medicine (e.g. red yeast rice products) for lipid-lowering * Receiving treatment with systemic corticosteroids (unless on stable therapy for at lest 6 weeks for replacement for pituitary/adrenal/hypogonadal disease) * Uncontrolled illness or infection